Biovail Corp. International news

BVF accepted a proposal under which former partner Hoechst-Roussell Pharmaceuticals Inc. will pay $7.5 million to the Toronto company as part of a series of agreements settling disputes relating to BVF's Diltiazem HCl cardiovascular drug.

Hoechst also will withdraw or otherwise dismiss the patent-related complaint filed by Marion Merrell Dow and Carderm Capital L.P. against Hoechst in the U.S. District Court in New Jersey; will use its best efforts to have Elan Corp. Plc withdraw or dismiss a similar complaint; and withdraw the citizen's petition filed by MMD with the FDA. Hoechst is acquiring MMD. ...